The Food and Drug Administration yesterday updated its Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioid analgesics, and extended the same requirements to immediate-release opioid analgesic products. The REMS applies to 347 opioid analgesics intended for outpatient use. Among other changes, the updates modify the prescriber education blueprint to include more information on pain management and require manufacturers to make training available to other, non-physician prescribers, such as nurses and pharmacists involved in pain management. FDA announced the planned updates last year. In other news, the Centers for Disease Control and Prevention recently released a resource to help health care providers implement its guidelines for prescribing opioids for chronic pain.

Related News Articles

Headline
Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-Tenn., today convened a hearing on “Managing Pain During the Opioid Crisis”…
Headline
The Centers for Medicare…
Headline
The Centers for Medicare…
Insights and Analysis
Also in this weekly roundup of health care news: Providence St. Joseph Health launches population health company; Aetna, others try new approach to educate…
Headline
The Health Resources and Services Administration's Federal Office of Rural Health Policy plans to award about 75 grants of up to $1 million each to expand…
Headline
The White House Office of National Drug Control Policy yesterday released its national drug control strategy, intended to guide federal efforts to reduce the…